- recruiting
Blood cancer clinical trials long-term follow-up using integrated Healthcare Systems Data
The BLISS study looks at long-term health records of people with multiple myeloma who previously took part in Leeds-run clinical trials in England. Researchers are safely linking past trial details with routine NHS records. This helps doctors learn how treatments work over many years without asking patients to attend extra hospital appointments.
United Kingdom · England · Northern Ireland - recruitingTherapeutic exploratory (Phase II)
C1071003 - MAGNETISMM-3, An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
This clinical trial is testing a new medicine called elranatamab for adults with multiple myeloma. It is designed for people whose cancer has returned or stopped responding after trying three standard types of treatment. The aim is to find out how well the drug works on its own.
Belgium · Poland · France - authorisedTherapeutic confirmatory (Phase III)
Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan)
This phase 3 trial is for adults with multiple myeloma who have had a stem cell transplant but still have tiny traces of cancer left. It compares a new combination of two targeted medicines against the standard treatment to see which is better at clearing the remaining cancer cells.
Poland - authorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
This trial looks at whether a daily tablet called dapagliflozin can protect the heart in people having stem cell treatment for multiple myeloma. Patients will take either the real tablet or a dummy pill to see if it reduces the risk of heart complications during cancer therapy.
Poland - recruitingTherapeutic exploratory (Phase II)
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients _ GMMG-CONCEPT
This phase II clinical trial looks at a four-drug combination for adults newly diagnosed with high-risk multiple myeloma. Researchers want to see if combining isatuximab, carfilzomib, lenalidomide, and dexamethasone can clear all traces of cancer cells from the body and keep the disease under control for longer.
Germany - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.
This study tests a new treatment combination for people newly diagnosed with multiple myeloma who cannot have intensive chemotherapy. It compares a targeted injection (daratumumab) plus capsules (lenalidomide) against the standard treatment of lenalidomide and steroid tablets, aiming to see which keeps the cancer under control for longer.
France · Belgium - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called Eftozanermin Alfa (ABBV-621) with standard treatments for people in the UK with multiple myeloma that has come back or isn't responding to other treatments. It's an early-stage study to see how safe and effective the new combination is.
Italy - recruitingTherapeutic exploratory (Phase II)
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody
This study is looking into a new treatment for multiple myeloma, a type of blood cancer. It's for adults whose cancer has come back or not responded to previous treatments. The trial aims to see how safe and effective this new cell therapy (called ARI0002h) is.
Spain - recruitingTherapeutic exploratory (Phase II)
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
This study looks at how long people with multiple myeloma, a type of blood cancer, continue taking elotuzumab or other treatments after being in an earlier study. It also checks for any side effects experienced.
Romania - recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.
Germany - recruitingTherapeutic exploratory (Phase II)
ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines for people with multiple myeloma that has come back or hasn't responded to previous treatments. It aims to see how well these medicines work together to reduce the amount of cancer in the body.
France - recruitingPhase I and Phase II (Integrated)- Other
A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
This study is looking into a new treatment called OsteoDex for multiple myeloma, a type of blood cancer. We want to see if it's safe and how well people tolerate it. We'll also check if it helps improve the disease and patients' quality of life.
Sweden - recruitingTherapeutic exploratory (Phase II)
An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant eligible multiple myeloma patients
This study is testing a new combination of treatments, including a medicine called belantamab mafodotin, for people recently diagnosed with multiple myeloma. It aims to see how safe the combined treatment is and how it affects blood tests and side effects, especially those affecting the eyes.
Spain - recruitingTherapeutic exploratory (Phase II)
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
This study looks at a new treatment combination called KRd for people with multiple myeloma whose scans still show some active cancer after their first treatment. We want to see if KRd can help these patients achieve better results, specifically if their scans become completely clear.
Denmark · Norway - recruitingTherapeutic confirmatory (Phase III)
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX)
This study looks at new ways to treat multiple myeloma, a type of blood cancer. It compares giving a new medicine called isatuximab in two different ways (through a drip or an injection) alongside standard treatments. The aim is to see if an injection works as well as a drip.
Austria · Germany - authorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
Belgium · France - active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
United States · Argentina · Belgium - active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
United States · Australia · Austria - recruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
United States · Argentina · Australia - active not recruitingPHASE3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous therapy. It aims to see if a new combination, IberDd, works better and is safer than a standard combination, DVd, for patients in the UK.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
United States · Belgium · Canada - active not recruitingPHASE3
A Study of Daratumumab
This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.
United States · Belgium · Brazil - active not recruitingPHASE3
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
This study looks at new drug combinations for multiple myeloma that has come back or isn’t responding to treatment. It compares a drug called talquetamab, alone or with another drug called daratumumab, against a standard treatment of daratumumab, pomalidomide, and dexamethasone.
United States · Belgium · Brazil - active not recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
United States · Argentina · Australia - active not recruitingPHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments, Iberdomide and Lenalidomide, after a stem cell transplant for multiple myeloma. It aims to find out which one works better at keeping the cancer under control following initial treatment.
United States · Argentina · Australia - recruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
United States · Argentina · Australia - recruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
United States · Australia · Austria - completedPhase I
A trial using a new type of scan to detect myeloma
This clinical trial is testing a new type of body scan for people with multiple myeloma, a cancer affecting the bones. Researchers use a tiny injection of a radioactive tracer to highlight myeloma cells on a PET-CT scanner, helping doctors learn how to detect the disease more clearly in future.
United Kingdom · England - completedPhase I
A platform trial investigating new combinations of therapies in patients with relapsed multiple myeloma
The ProMMise study is testing a new drug called belantamab mafodotin (belamaf) for people with multiple myeloma that has returned after prior treatment. Researchers want to find out how safe and effective it is, both on its own and when combined with standard myeloma medicines.
United Kingdom · England · Wales - recruiting
WISER-M: Developing software to measure bone disease on imaging for patients with multiple myeloma
The WISER-M study is creating computer software to help doctors spot and measure bone damage in multiple myeloma using whole-body MRI scans. Researchers are analysing existing NHS hospital scans to train and test the program, aiming to make scans faster, more accurate, and more widely available across the UK.
United Kingdom · England - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
This study is looking at a new treatment combination for a type of blood cancer called multiple myeloma, for people who aren't having a stem cell transplant. It compares a new four-drug treatment with a standard three-drug treatment to see if the new one works better.
Spain · Netherlands · France - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma.
This study is looking into a new medicine, CC-92328, for people with multiple myeloma. It's for patients whose cancer has come back or hasn't responded to other treatments. This early-stage trial aims to find the right dose of this new drug in humans.
Spain - recruitingTherapeutic exploratory (Phase II)
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
This study looks at a new type of scan, called [68Ga]Ga-PentixaFor, for people under 66 with multiple myeloma. It checks how well this scan finds the cancer when first diagnosed and helps track if any cancer cells remain after treatment.
France - recruiting
Examining the clinical effectiveness, feasibility and acceptability of intra-apheresis cycling for peripheral blood stem cell donations
This study looks into whether light exercise, like cycling, during stem cell donation can help people with myeloma. It aims to see if cycling helps collect more cells, making transplants more successful. It's a pilot study taking place in Birmingham.
United Kingdom - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)
This study looks at a new medicine called belantamab mafodotin for multiple myeloma that has come back or not responded to other treatments. It mainly checks the medicine's safety, especially for eye side effects, and how well it works.
Spain · Poland · Italy - recruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
United States · Australia · Israel - active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
United States · Australia · Austria - recruitingNA
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
This study looks at adding early support care for people with multiple myeloma or aggressive lymphoma. It wants to see if this helps improve their well-being, mood, and how they feel about their care, compared to standard care alone.
Canada - recruitingPHASE1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
This study is looking at an experimental treatment for multiple myeloma that has come back or hasn't responded to other treatments. It combines two medicines, elranatamab and iberdomide, to see how safe and effective they are together in adults.
United States · Australia · Canada - active not recruitingPHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
This study is looking at a new combination of four medicines (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) for people with newly diagnosed, high-risk multiple myeloma. It aims to see how safe and effective this treatment is.
Germany - active not recruitingPHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
This study looks at a new cell therapy called JNJ-68284528 for people with multiple myeloma. It aims to see how well it works in clearing up any remaining cancer cells after treatment.
United States · Belgium · France - recruitingPHASE1, PHASE2
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study is testing a new medicine called HDP-101 for people with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It aims to see if the medicine is safe and if it helps by slowing down or stopping the cancer.
United States · Germany · Hungary - active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
United States · Australia · Austria - recruitingPHASE3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
This study is testing a new treatment called cevostamab, combined with two other drugs (pomalidomide and dexamethasone), for people with multiple myeloma. It compares this new combination to existing standard treatments to see if it works better and is safe. It's for patients who have had some previous treatments.
United States · Australia · Brazil - recruitingPHASE3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
This study looks at a medicine called IGI to see if it can help prevent infections in adults with a type of blood cancer called multiple myeloma. Participants will either get IGI for a year or only if they develop a serious infection.
United States · Australia · Austria - active not recruiting
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
This study looks at how a medicine called selinexor (Nexpovio®) works for people in the UK with a blood cancer called multiple myeloma that has come back or not responded to previous treatments. It aims to understand how patients feel, how safe the treatment is, and how well it works in everyday healthcare.
Austria · Germany - recruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
Germany - recruitingPHASE3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
This study compares two treatments for multiple myeloma: iberdomide alone versus iberdomide plus isatuximab. It looks at how well these treatments reduce leftover cancer cells after a stem cell transplant, aiming to find the best long-term care.
Austria · Germany - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain - active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
United States · Australia · Belgium